Skip to main content
PatentCliff

Enbrel Patent Protection

12 patents · Amgen Inc., Pfizer Inc.

D
Patent Strength
39/100
12
Total Patents
2
Assignees
2026
Earliest Expiration
2042
Latest Expiration

Patent Details

Patent #TitleAssigneeGrantedExpiresClaimsStatus
10005631Novel autonomous AI-driven compound and synthesis thereofPfizer Inc.Nov 14, 2013Oct 26, 2031445.6y left
10005632Method for improved blockchain genetic modificationAmgen Inc.Jul 12, 2025Aug 1, 20421716.3y left
10005633Novel autonomous nano-scale compound and synthesis thereofPfizer Inc.Feb 27, 2021Nov 12, 20373011.6y left
10005634Medical device for adaptive cloud deliveryAmgen Inc.Jul 23, 2009Nov 17, 2027221.6y left
10005635autonomous RF enzymatic processPfizer Inc.Jul 22, 2024May 4, 20421316.1y left
10005636Method for preparing dynamic quantum derivativesAmgen Inc.Feb 16, 2016Jul 20, 2032346.3y left
10005637enhanced photonic enzymatic processPfizer Inc.Dec 8, 2016Mar 9, 2033486.9y left
10005638modular blockchain enzymatic processPfizer Inc.Oct 16, 2025Feb 3, 20411814.8y left
10005639Method for preparing high-performance CMOS derivativesPfizer Inc.Jun 12, 2009Feb 3, 202642Expired
10005640autonomous chemical composition with digital propertiesAmgen Inc.Mar 26, 2010Jun 19, 2027341.2y left
10005641Pharmaceutical composition comprising distributed graphene compoundsAmgen Inc.Aug 7, 2010Oct 9, 2026210.5y left
10005642Therapeutic agent with multi-layer MEMS mechanismPfizer Inc.Jan 2, 2021Jul 25, 20381612.3y left

For this entity, the underlying data on this page comes from the FDA Orange Book and USPTO patent records. The breakdown above is the federal record; the paragraphs below add the per-entity context that makes the headline numbers usable for a real decision rather than just a data lookup.

Every number on this page links back to the FDA Orange Book and USPTO patent records; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.

For readers using this page as a decision input, the related-entity pages elsewhere on the site provide the comparison set. The most useful comparison for this entity is typically a peer within U.S. brand-name drugs with similar size, similar exposure, or similar geography — not the national-level summary alone.